Literature DB >> 22169799

Animal models: Towards a myeloma mouse.

Sarah DeWeerdt.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22169799     DOI： 10.1038/480S38a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  6 in total

1.  Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Authors:  Jinsong Hu; Damian R Handisides; Els Van Valckenborgh; Hendrik De Raeve; Eline Menu; Isabelle Vande Broek; Qian Liu; Jessica D Sun; Ben Van Camp; Charles P Hart; Karin Vanderkerken
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

2.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.

Authors:  S Yaccoby; B Barlogie; J Epstein
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

3.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

Authors:  Marta Chesi; Davide F Robbiani; Michael Sebag; Wee Joo Chng; Maurizio Affer; Rodger Tiedemann; Riccardo Valdez; Stephen E Palmer; Stephanie S Haas; A Keith Stewart; Rafael Fonseca; Richard Kremer; Giorgio Cattoretti; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

4.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Authors:  Mariateresa Fulciniti; Pierfrancesco Tassone; Teru Hideshima; Sonia Vallet; Puru Nanjappa; Seth A Ettenberg; Zhenxin Shen; Nipun Patel; Yu-Tzu Tai; Dharminder Chauhan; Constantine Mitsiades; Rao Prabhala; Noopur Raje; Kenneth C Anderson; David R Stover; Nikhil C Munshi
Journal:  Blood       Date:  2009-05-05       Impact factor: 22.113

5.  A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells.

Authors:  T Calimeri; E Battista; F Conforti; P Neri; M T Di Martino; M Rossi; U Foresta; E Piro; F Ferrara; A Amorosi; N Bahlis; K C Anderson; N Munshi; P Tagliaferri; F Causa; P Tassone
Journal:  Leukemia       Date:  2011-01-14       Impact factor: 11.528

6.  The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.

Authors:  Daniel R Carrasco; Kumar Sukhdeo; Marina Protopopova; Raktim Sinha; Miriam Enos; Daniel E Carrasco; Mei Zheng; Mala Mani; Joel Henderson; Geraldine S Pinkus; Nikhil Munshi; James Horner; Elena V Ivanova; Alexei Protopopov; Kenneth C Anderson; Giovanni Tonon; Ronald A DePinho
Journal:  Cancer Cell       Date:  2007-04       Impact factor: 31.743
  6 in total
  9 in total

1.  PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.

Authors:  Miao Li; Fangfang Shi; Xiong Fei; Songyan Wu; Di Wu; Meng Pan; Shouhua Luo; Ning Gu; Jun Dou
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

2.  Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authors:  Maria T Di Martino; Emanuela Leone; Nicola Amodio; Umberto Foresta; Marta Lionetti; Maria R Pitari; Maria E Gallo Cantafio; Annamaria Gullà; Francesco Conforti; Eugenio Morelli; Vera Tomaino; Marco Rossi; Massimo Negrini; Manlio Ferrarini; Michele Caraglia; Masood A Shammas; Nikhil C Munshi; Kenneth C Anderson; Antonino Neri; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2012-10-03       Impact factor: 12.531

3.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

Review 4.  Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.

Authors:  P Tassone; P Neri; R Burger; M T Di Martino; E Leone; N Amodio; M Caraglia; P Tagliaferri
Journal:  Curr Cancer Drug Targets       Date:  2012-09       Impact factor: 3.428

5.  Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.

Authors:  Nassera Aouali; Angeliki Broukou; Manon Bosseler; Olivier Keunen; Vincent Schlesser; Bassam Janji; Valerie Palissot; Philippe Stordeur; Guy Berchem
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

6.  Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.

Authors:  Marilène Binsfeld; Yves Beguin; Ludovic Belle; Eléonore Otjacques; Muriel Hannon; Alexandra Briquet; Roy Heusschen; Pierre Drion; Jenny Zilberberg; Bjarne Bogen; Frédéric Baron; Jo Caers
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

7.  Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model.

Authors:  Cuiping Yang; Fei Xiong; Jun Dou; Jun Xue; Xi Zhan; Fangfang Shi; Miao Li; Songyan Wu; Shouhua Luo; Tianzhu Zhang; Yu Zhang; Ji Ming; Ning Gu
Journal:  Oncotarget       Date:  2015-09-29

Review 8.  Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

Authors:  Jinsong Hu; Els Van Valckenborgh; Eline Menu; Elke De Bruyne; Karin Vanderkerken
Journal:  Dis Model Mech       Date:  2012-11       Impact factor: 5.758

9.  Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria.

Authors:  Xingxing Jian; Yinghong Zhu; Jian Ouyang; Yihui Wang; Qian Lei; Jiliang Xia; Yongjun Guan; Jingyu Zhang; Jiaojiao Guo; Yanjuan He; Jinuo Wang; Jian Li; Jingchao Lin; Mingming Su; Guancheng Li; Minghua Wu; Lugui Qiu; Juanjuan Xiang; Lu Xie; Wei Jia; Wen Zhou
Journal:  Microbiome       Date:  2020-05-28       Impact factor: 14.650
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.